Key Financial Performance FY25-26

Annual Financials (Figures in ₹ Lakhs):

  • Revenue from Operations: ₹65,464.70 lakhs (₹654.62 Cr), representing 70% year-over-year growth from FY24-25 revenue of ₹38,624 lakhs
  • EBITDA: ₹2,111.38 lakhs (₹21.11 Cr), showing 423% growth from previous year's ₹403.2 lakhs
  • EBITDA Margin: 3.22% compared to 1.043% in FY24-25 (210% improvement)
  • Profit Before Tax (PBT): ₹1,478.8 lakhs, surging 1361% from ₹101.17 lakhs in FY24-25
  • Profit After Tax (PAT): ₹1,093 lakhs (₹10.93 Cr), achieving 2276% growth from ₹46.00 lakhs in previous year
  • PAT Margin: 1.67% compared to 0.12% in FY24-25 (1291% improvement)
  • Tax Expense: ₹355.9 lakhs for FY25-26 compared to ₹55.15 lakhs in FY24-25
  • Depreciation & Amortization: ₹406.3 lakhs compared to ₹294.7 lakhs in previous year
  • Finance Cost: ₹226.35 lakhs compared to ₹6.60 lakhs in FY24-25
  • Other Income: ₹2.1 lakhs compared to ₹4.24 lakhs in previous year

Quarterly Financial Performance Q4 FY25-26 (Figures in ₹ Lakhs):

  • Revenue from Operations: ₹24,830.19 lakhs, showing 53.6% quarter-over-quarter growth from Q3 FY25-26 revenue of ₹16,164 lakhs
  • EBITDA: ₹936.74 lakhs, with 38% growth from previous quarter's ₹596.32 lakhs
  • EBITDA Margin: 3.77% compared to 3.7% in Q3
  • PBT: ₹560.12 lakhs, showing 12.8% growth from ₹496.52 lakhs in Q3
  • PAT: ₹174.28 lakhs, decreasing 58.21% from ₹417.08 lakhs in Q3 due to tax adjustments
  • Tax Expense: ₹355.9 lakhs in Q4 compared to ₹79.44 lakhs in Q3
  • The presentation notes that PAT for Q4 appears lower due to impact of deferred tax adjustments recognized during the last quarter

Earnings Per Share:

  • Average weighted EPS: ₹2.50 for FY25-26
  • Diluted EPS: ₹1.93 for FY25-26

Operational Metrics

Production Performance:

  • Q4 FY25-26 production volume: 1,239 MT, representing 85% capacity utilization
  • Production showed significant ramp-up from Q1 volume of 463 MT to Q4 volume of 1,239 MT
  • Installed manufacturing capacity: ~4,200 TPA (Tons Per Annum)

Market Presence & Sales Distribution:

  • Total consumers and traders globally: 200+
  • Domestic sales (9M FY25-26): ₹456.22 crore compared to full-year FY24-25 domestic sales of ₹241.25 crore
  • Export sales (FY25-26): ₹198.39 crore, exceeding full-year FY24-25 exports of ₹90.890 crore
  • Geographic reach: 14+ Indian states and 10+ international locations across 3 continents

Product Portfolio:

  • 7+ API SKUs including key products: Amoxicillin, Cloxacillin sodium, Flucloxacillin sodium, Dicloxacillin sodium, Cephalexin, Ampicillin, Cephadroxil
  • Company is developing dedicated plants for Amoxicillin and other penicillin-based products

Corporate Structure & Capital

Shareholding Pattern (as on 31st March 2026):

  • Promoter and Promoter Group: 60.86%
  • Public: 39.14%
  • Total shares: 4,90,13,000
  • Paid-up Capital: ₹4901.30 lakhs

Company Background:

  • Incorporated: 1991
  • Listed on: BSE
  • Business: Manufacturing of Bulk Drugs/Intermediates and contract manufacturing
  • Land bank: 6+ acres
  • Employee strength: Increased by 17% during the year

Strategic Initiatives & Future Outlook

Expansion Plans:

  • Driving strategic expansion through backward integration to enhance capacity and efficiency
  • Focused on achieving WHO-GMP certification to strengthen global quality standards
  • Development of dedicated manufacturing plants for key antibiotic products

Business Strategy Pillars:

1. Continuous Innovation through R&D investments and process engineering

2. Reliable Supply through integrated manufacturing and strong vendor partnerships

3. World Class Quality with internationally aligned manufacturing standards

4. Customer Engagement focusing on quality products and timely deliveries

Leadership Team:

  • Ranjan Jain: Managing Director with over 25+ years of entrepreneurial experience, overseeing strategic diversification
  • Sanjeev Agrawal: Whole-time Director with over two decades of experience in sales and marketing
  • Suninder Veer Singh: Chief Financial Officer with around 30 years of experience in finance and operations

Disclaimer Notes

  • Presentation prepared by the Company based on information considered reliable but no representation or warranty expressed
  • Contains forward-looking statements subject to known and unknown risks and uncertainties
  • No responsibility or liability accepted for any loss or damage arising from the presentation contents